Showing results (1691-1700 of 3,157) with videos related to

Sort By:
Pageof 316
Neuro-Oncology|October 21, 2021
Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG)Matthias Preusser, Antonio Silvani, Emilie Le Rhun, et al.
Neuro-Oncology|October 5, 2021
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018Quinn T Ostrom, Gino Cioffi, Kristin Waite, et al.
Neuro-Oncology|February 25, 2022
Combination of BMI1 and MAPK/ERK inhibitors is effective in medulloblastomaSara Badodi, Nicola Pomella, Yau Mun Lim, et al.
Neuro-Oncology|February 9, 2022
Surveillance imaging frequency in adult patients with lower-grade (WHO Grade 2 and 3) gliomasJasmin Jo, Martin J van den Bent, Burt Nabors, et al.
Neuro-Oncology|July 28, 2022
Genetic predisposition and evolutionary traces of pediatric cancer risk: a prospective 5-year population-based genome sequencing study of children with CNS tumorsUlrik Kristoffer Stoltze, Jon Foss-Skiftesvik, Thomas van Overeem Hansen, et al.
Neuro-Oncology|October 17, 2021
Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor verteporfin in preclinical glioblastoma modelsAnne Marie Barrette, Halle Ronk, Tanvi Joshi, et al.
Neuro-Oncology|October 26, 2021
12p gain is predominantly observed in non-germinomatous germ cell tumors and identifies an unfavorable subgroup of central nervous system germ cell tumorsKaishi Satomi, Hirokazu Takami, Shintaro Fukushima, et al.
Neuro-Oncology|July 22, 2022
Influence of county-level geographic/ancestral origin on glioma incidence and outcomes in US HispanicsKyle M Walsh, Corey Neff, Melissa L Bondy, et al.
Neuro-Oncology|July 18, 2022
Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trialAndrew B Lassman, Stephanie L Pugh, Tony J C Wang, et al.
Neuro-Oncology|October 14, 2021
Characterization and prognosis of temozolomide-induced aplastic anemia in patients with central nervous system malignanciesAlbert K Park, Anem Waheed, Deborah A Forst, et al.
Pageof 316